JP4694777B2 - Viable bacteria composition - Google Patents
Viable bacteria composition Download PDFInfo
- Publication number
- JP4694777B2 JP4694777B2 JP2003284828A JP2003284828A JP4694777B2 JP 4694777 B2 JP4694777 B2 JP 4694777B2 JP 2003284828 A JP2003284828 A JP 2003284828A JP 2003284828 A JP2003284828 A JP 2003284828A JP 4694777 B2 JP4694777 B2 JP 4694777B2
- Authority
- JP
- Japan
- Prior art keywords
- vitamin
- bifidobacteria
- present
- growth
- viable bacteria
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Description
本発明はビフィズス菌を含有する組成物及びチュアブル剤、並びにビフィズス菌の増殖促進方法及び増殖促進剤に関する。 The present invention relates to a composition and chewable agent containing bifidobacteria, a method for promoting the growth of bifidobacteria, and a growth promoter.
ビフィズス菌、乳酸菌は腸内細菌叢のいわゆる善玉菌であり、便秘、腹部膨満感の改善等の整腸作用を有するため医薬品又は食品として飲料や錠剤等の形態として広く服用されている。乳酸菌等を含有した組成物としては、特許文献１に、凍結乾燥された納豆菌、乳酸菌、酵母、ビタミン類及び糖分が混和され固形化された食品が開示され、また、特許文献２には、乳酸菌、糖化菌及び酪酸菌を有効成分とする３種菌共生混合物が開示されている。更に、特許文献３には、納豆菌、乳酸菌、オリゴ糖、玄米からなる抗酸化性組成物が開示されている。
ビフィズス菌は経口的に服用しても腸内に定着しにくいといわれており、服用後腸内において増殖させることが課題となっている。また、飲料としての形態は持ち運びに難点があり、錠剤は服用時に水を必要とするという欠点があり、剤形の点からも更に改善の余地があった。また前述の文献には、腸内浄化作用、整腸作用、抗酸化作用、抗潰瘍作用等を有することが示されているが、ビフィズス菌を腸内において増殖させる手段は開示されていない。本発明者は、これら課題を解決すべく鋭意検討し、以下に示す手段により課題を解決できることを見出し本発明を完成した。 It is said that bifidobacteria are difficult to settle in the intestine even if taken orally, and it is a problem to grow in the intestine after taking. Moreover, the form as a drink has a difficulty in carrying, the tablet has the fault of requiring water at the time of taking, and there was room for improvement from the point of a dosage form. In addition, the above-mentioned documents show that they have intestinal purification action, intestinal regulation action, antioxidant action, anti-ulcer action, etc., but do not disclose means for growing bifidobacteria in the intestine. The present inventor has intensively studied to solve these problems, and found that the problems can be solved by the following means and completed the present invention.
本発明は、ビフィズス菌に、ビタミンＢ２、ビタミンＢ６及びビタミンＣを配合することによるビフィズス菌の増殖促進方法、ビタミンＢ２、ビタミンＢ６及びビタミンＣを含有する、ビフィズス菌の増殖促進剤、並びにビフィズス菌、ビタミンＢ２、ビタミンＢ６及びビタミンＣを含有する組成物又はチュアブル剤である。 The present invention relates to a method for promoting the growth of bifidobacteria by adding vitamin B2, vitamin B6 and vitamin C to bifidobacteria, a bifidobacteria growth promoter containing vitamin B2, vitamin B6 and vitamin C, and bifidobacteria , Vitamin B2, Vitamin B6, and Vitamin C.
本発明の増殖促進方法及び増殖促進剤により、ビフィズス菌を腸内において有効に増殖させることができる。 By the growth promoting method and growth promoting agent of the present invention, bifidobacteria can be effectively grown in the intestine.
本発明におけるビフィズス菌とは、ビフィドバクテリウム属に属する菌を意味し、例えばビフィダム菌、ブレーベ菌、ロンガム菌又はアンドレッセンティス菌等を挙げることができ、特にBifidobacterium longum NTが好ましい。 The bifidobacteria in the present invention means a bacterium belonging to the genus Bifidobacterium, and examples thereof include bifidum bacterium, breve bacterium, longum bacterium, and andrgentis bacterium, and Bifidobacterium longum NT is particularly preferable.
本発明におけるビフィズス菌の含有量は、それぞれ一回に服用される菌数では通常１０5〜１０9cfuであり、好ましくは１０6〜１０9cfuである。重量に換算すると、一回の服用当たり１０〜２００ｍｇ、好ましくは２０〜１５０ｍｇである。 The content of bifidobacteria in the present invention is usually 10 5 to 10 9 cfu, preferably 10 6 to 10 9 cfu in terms of the number of bacteria taken at one time. In terms of weight, it is 10 to 200 mg, preferably 20 to 150 mg per dose.
本発明においては、ビフィズス菌に、ビタミンＢ２、ビタミンＢ６及びビタミンＣを添加することにより、ビフィズス菌を増殖促進することができる。ビタミンＢ２はリボフラビンとも呼ばれ、リン酸リボフラビン、補酵素型リボフラビン等の種類があるが、特に遊離体が好ましい。ビタミンＢ６は、ピリドキシンとも呼ばれ、ビタミンＣは、アスコルビン酸とも呼ばれる。本発明においては、ビタミンＢ２は一回の服用当たり５〜３０ｍｇ、好ましくは１０〜２０ｍｇであり、ビタミンＢ６は一回の服用当たり１０〜１００ｍｇ、好ましくは１５〜５０ｍｇであり、ビタミンＣは一回の服用当たり１００〜１０００ｍｇ、好ましくは２００〜５００ｍｇである。 In the present invention, the growth of bifidobacteria can be promoted by adding vitamin B2, vitamin B6 and vitamin C to bifidobacteria. Vitamin B2 is also called riboflavin and includes riboflavin phosphate, coenzyme riboflavin, etc., but the free form is particularly preferable. Vitamin B6 is also called pyridoxine, and vitamin C is also called ascorbic acid. In the present invention, vitamin B2 is 5 to 30 mg, preferably 10 to 20 mg per dose, vitamin B6 is 10 to 100 mg, preferably 15 to 50 mg per dose, and vitamin C is used once. 100-1000 mg per dose, preferably 200-500 mg.
本発明では、ビフィズス菌と、ビタミンＢ２、ビタミンＢ６及びビタミンＣを含有する組成物又はチュアブル剤を服用すると、消化管内においてビフィズス菌の増殖が促進され、排便促進作用、整腸作用がもたらされるが、これらの作用が本願発明の目的である。 In the present invention, when a composition or chewable agent containing bifidobacteria and vitamin B2, vitamin B6 and vitamin C is taken, the growth of bifidobacteria in the digestive tract is promoted, resulting in a defecation promoting action and an intestinal regulating action. These actions are the object of the present invention.
本発明にかかる組成物は、例えば通常の錠剤とするためには、乳糖、デンプン、結晶セルロース等の賦形剤、ヒドロキシプロピルセルロース等の結合剤を混合して溶媒を用いて造粒、乾燥後、ステアリン酸等の滑沢剤を添加して打錠し通常の錠剤を製造することができる。 For example, in order to obtain a normal tablet, the composition according to the present invention is mixed with excipients such as lactose, starch and crystalline cellulose, and a binder such as hydroxypropyl cellulose, and after granulation and drying using a solvent. Ordinary tablets can be produced by tableting with a lubricant such as stearic acid.
更に本発明にかかるチュアブル剤は、ビフィズス菌、ビタミンＢ２、ビタミンＢ６及びビタミンＣを含有するチュアブル剤である。本発明にかかるチュアブル剤を製造するには、ビタミンＢ２、ビタミンＢ６及びビタミンＣにショ糖、マンニトール等の甘味を有する賦形剤とヒドロキシプロピルセルロース等の結合剤、更に必要に応じ矯味矯臭剤を混合し、溶媒を加えて造粒、乾燥後、ビフィズス菌、滑沢剤を添加、打錠して得ることができる。打錠圧は一般の錠剤を製造するよりも高くし、一般に崩壊剤を使用しない。チュアブル剤とは、口中において徐々に溶かすか又はかみ砕いて服用するものであり、日本薬局方製剤総則におけるトローチ剤と同様な製剤であるが、本発明にかかるチュアブル剤は、口腔粘膜又は咽頭粘膜局所に対する作用を期待するものではない。本発明にかかる組成物又はチュアブル剤を服用すると、消化管内においてビフィズス菌の増殖が促進され、排便促進作用、整腸作用がもたらされるため、本発明は、ビフィズス菌、ビタミンＢ２、ビタミンＢ６及びビタミンＣを含有する排便促進剤又は整腸剤を提供するものである。 Furthermore, the chewable agent according to the present invention is a chewable agent containing bifidobacteria, vitamin B2, vitamin B6 and vitamin C. In order to produce the chewable preparation according to the present invention, vitamin B2, vitamin B6 and vitamin C are mixed with an excipient having sweetness such as sucrose and mannitol, a binder such as hydroxypropylcellulose, and a flavoring agent if necessary. After mixing, granulating and drying by adding a solvent, bifidobacteria and a lubricant are added and tableted. The tableting pressure is higher than that for producing ordinary tablets, and generally no disintegrant is used. A chewable agent is one that is gradually dissolved or chewed in the mouth and is a formulation similar to the troche in the Japanese Pharmacopoeia General Rules for Preparation, but the chewable agent according to the present invention is an oral mucosa or pharyngeal mucosa. It does not expect local effects. When the composition or chewable agent according to the present invention is taken, the growth of bifidobacteria is promoted in the gastrointestinal tract, resulting in a defecation promoting action and an intestinal regulating action. Therefore, the present invention includes bifidobacteria, vitamin B2, vitamin B6 and vitamins. A defecation promoter or intestinal regulating agent containing C is provided.
以下に、実施例により本発明を説明する。 Hereinafter, the present invention will be described by way of examples.
実施例１
ＭＣＭ培地１Ｌに表１で示す量のビタミンＢ２、ビタミンＢ６及びビタミンＣを加えビフィズス菌（Bifidobacterium longum NT）約１０8cfu/Lを接種し、培地１０ｍＬを入れた試験管中で３７℃２４時間静置嫌気培養した。接種時と培養２４時間後の生菌数を測定した結果を表２に示した。表２より明らかなようにビタミン無添加ではビフィズス菌の増殖はわずかであったが、ビタミン添加によりビフィズス菌は約１００倍に増殖した。以上より、ビタミンＢ２、ビタミンＢ６及びビタミンＣにビフィズス菌の増殖を促進する作用を有することが明らかである。
Example 1
Vitamin B2, vitamin B6, and vitamin C in the amounts shown in Table 1 are added to 1 L of MCM medium, inoculated with about 10 8 cfu / L of Bifidobacterium longum NT, and incubated at 37 ° C. for 24 hours in a test tube containing 10 mL of medium. Static anaerobic culture was performed. The results of measuring the number of viable bacteria at the time of inoculation and after 24 hours of culture are shown in Table 2. As apparent from Table 2, the growth of bifidobacteria was slight when no vitamin was added, but the bifidobacteria grew about 100 times by the addition of vitamin. From the above, it is clear that vitamin B2, vitamin B6 and vitamin C have an action of promoting the growth of bifidobacteria.
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003284828A JP4694777B2 (en) | 2003-08-01 | 2003-08-01 | Viable bacteria composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003284828A JP4694777B2 (en) | 2003-08-01 | 2003-08-01 | Viable bacteria composition |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP36225499A Division JP3478773B2 (en) | 1999-12-21 | 1999-12-21 | Viable bacteria composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004026840A JP2004026840A (en) | 2004-01-29 |
| JP4694777B2 true JP4694777B2 (en) | 2011-06-08 |
Family
ID=31185547
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003284828A Expired - Lifetime JP4694777B2 (en) | 2003-08-01 | 2003-08-01 | Viable bacteria composition |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP4694777B2 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021535086A (en) * | 2018-08-29 | 2021-12-16 | ディーエスエム アイピー アセッツ ビー.ブイ.Dsm Ip Assets B.V. | Formulation to improve intestinal health |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS59132884A (en) * | 1983-01-20 | 1984-07-31 | Dai Ichi Seiyaku Co Ltd | Composition for promoting propagation of bifidobacterium |
| JPS6037953A (en) * | 1983-08-11 | 1985-02-27 | Herusu Eido:Kk | Nutrient supplement food composed mainly of calcium |
| JPS6188859A (en) * | 1984-10-05 | 1986-05-07 | Fuji Yakuhin Kogyo Kk | Food containing lactobacillus bifidus |
| JPS61231966A (en) * | 1985-04-06 | 1986-10-16 | Nikken Food Honsha Kk | Food for multiplying useful bacterium in intestine |
| US4756913A (en) * | 1985-09-30 | 1988-07-12 | Khorkova Evgenia A | Sour milk product |
| DE4132296C1 (en) * | 1991-09-27 | 1992-12-17 | Karl Heinz 8081 Schoengeising De Hoelzel | Enzymic metabolic prod. prepn. for intestinal disorders etc. - obtd. from pathogenic lacto- and bifido- bacteria from the gut |
| JP3559063B2 (en) * | 1994-03-31 | 2004-08-25 | 雪印乳業株式会社 | Bifidobacterium growth promoter |
| JP4008974B2 (en) * | 1996-12-12 | 2007-11-14 | 森永乳業株式会社 | Bifidobacterium growth promoting composition and use thereof |
-
2003
- 2003-08-01 JP JP2003284828A patent/JP4694777B2/en not_active Expired - Lifetime
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021535086A (en) * | 2018-08-29 | 2021-12-16 | ディーエスエム アイピー アセッツ ビー.ブイ.Dsm Ip Assets B.V. | Formulation to improve intestinal health |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2004026840A (en) | 2004-01-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1609852B1 (en) | Bifidobacteria and preparations containing them | |
| US9549984B2 (en) | Probiotic oral dosage forms and method of enhancing the stability, thereof | |
| US8481025B2 (en) | Composition for maintaining healthy kidney function | |
| US6468525B1 (en) | Probiotic formulation | |
| KR20170053733A (en) | Prebiotic formulations and methods of use | |
| CN106974262B (en) | Application of intestinal probiotic bacillus in treating and preventing obesity and related diseases | |
| JP2002522393A (en) | Method for increasing the solubility of nutrient materials using symbiotic lactic acid producing bacteria | |
| US9980988B2 (en) | Compositions and methods for augmenting kidney function | |
| JP3478773B2 (en) | Viable bacteria composition | |
| WO2010114864A1 (en) | Probiotic oral dosage forms | |
| CA2478991C (en) | Compositions and methods for augmenting kidney function | |
| JP4694777B2 (en) | Viable bacteria composition | |
| CN110869035B (en) | Application of African adequacy bacterium to preparation of composition for preventing and/or treating lipid metabolism related diseases | |
| CN106974940B (en) | Application of probiotics of scleritis in treating and preventing obesity and related diseases | |
| EP1719518A1 (en) | Compositions comprising bacillus coagulans for increasing the solubility and bioavailability of nutritional minerals |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20060808 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070515 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20070702 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20070705 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070725 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070821 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20071211 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080123 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20080219 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080417 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20110224 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140304 Year of fee payment: 3 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 4694777 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140304 Year of fee payment: 3 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313117 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140304 Year of fee payment: 3 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140304 Year of fee payment: 3 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| EXPY | Cancellation because of completion of term |